← Browse by Condition
Medical Condition
idiopathic pulmonary fibrosis
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for idiopathic pulmonary fibrosis sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — idiopathic pulmonary fibrosis Clinical Trials
How many clinical trials are currently recruiting for idiopathic pulmonary fibrosis?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for idiopathic pulmonary fibrosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for idiopathic pulmonary fibrosis?
idiopathic pulmonary fibrosis research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a idiopathic pulmonary fibrosis clinical trial?
Eligibility criteria for idiopathic pulmonary fibrosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06967805 Phase 2
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment
164 pts
Location
United States, Argen...
Sponsor
Mediar Therapeutics
NCT05042219
Recruiting
Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
Enrollment
120 pts
Location
Germany
Sponsor
Ayham Daher
NCT07225296 Phase 1
Recruiting
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
Enrollment
72 pts
Location
United States
Sponsor
Genosco Inc.
NCT04160715
Recruiting
Korean Idiopathic Pulmonary Fibrosis Registry
Enrollment
3,000 pts
Location
South Korea
Sponsor
Seoul National University Hosp...
NCT06230822 Phase 1
Recruiting
Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Enrollment
9 pts
Location
China
Sponsor
Wuhan Optics Valley Vcanbiopha...
NCT05571059 Phase 2
Recruiting
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment
128 pts
Location
United States
Sponsor
Cumberland Pharmaceuticals
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology